AXERT by Johnson & Johnson is 5-ht 1d , 5-ht 1b , and 5-ht 1f receptors. Approved for cluster headache () 1. First approved in 2001.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AXERT (almotriptan) is a selective serotonin 5-HT1B/1D/1F receptor agonist (triptan class) approved for acute treatment of cluster headache. It works by binding serotonin receptors on cranial blood vessels and pain-transmitting neurons to rapidly abort headache attacks.
Product approaching loss of exclusivity with moderate competitive pressure (30); expect consolidation of commercial team and shift toward value-based positioning.
5-HT 1D , 5-HT 1B , and 5-HT 1F receptors. Almotriptan has weak affinity for 5-HT 1A and 5-HT 7 receptors, but has no significant affinity or pharmacological activity at 5-HT 2 , 5-HT 3 , 5-HT 4 , 5-HT 6 ; alpha or beta adrenergic; adenosine (A 1 , A 2 ); angiotensin (AT 1 , AT 2 ); dopamine (D 1 ,…
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
Worked on AXERT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on AXERT in its LOE-approaching phase means joining a mature, focused specialty headache team managing transition to generics and competing on value, access, and patient support. Career growth will depend on ability to drive managed care integration and retention strategies rather than market expansion.